Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
Prandoni
Paolo
P
University of Padua, Department of Cardiothoracic and Vascular Sciences, Thromboembolism Unit, Via Giustiniani 2, 35128 Padua, Italy. paoloprandoni@tin.it
Taher
Ali
A
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000069604:Dabigatran; D004311:Double-Blind Method; D005060:Europe; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009656:North America; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000401:mortality; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D014859:Warfarin; D000069604:Dabigatran